- Conditions
- Atrial Fibrillation
- Interventions
- triiodothyronine
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Manhasset, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 193
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bacterial Infection
- Interventions
- Apramycin (EBL-1003)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
- Interventions
- liothyronine, Placebo
- Drug · Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer
- Interventions
- Collection of plasma samples
- Other
- Lead sponsor
- DiaCarta, Inc.
- Industry
- Eligibility
- 30 Years to 85 Years · Male only
- Timeline
- 2020 – 2023
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Jacksonville, Florida • New York, New York + 2 more
- Conditions
- Thyroid Goiter, Hypothyroidism, Thyroid Cancer
- Interventions
- Levothyroxine, Liothyronine, Placebo
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- HIV Infections
- Interventions
- Infeccion de Amor (Love Infection)
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rectal Cancer
- Interventions
- Capecitabine, Irinotecan, EUS, Neoadjuvant Chemotherapy, Preoperative Radiation, Surgery, Adjuvant Chemotherapy
- Drug · Procedure
- Lead sponsor
- Gabi Chiorean, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 9
- States / cities
- Elkhart, Indiana • Fort Wayne, Indiana • Goshen, Indiana + 5 more
- Conditions
- Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
- Interventions
- Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test
- Device · Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years to 215 Months
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Breast Cancer
- Interventions
- ARIMIDEX (anastrazole), NOLVADEX (tamoxifen)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 60 Years and older · Female only
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 13
- States / cities
- Santa Rosa, California • New Britain, Connecticut • Torrington, Connecticut + 10 more
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Genetically modified CTLs
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Dental Caries in Children
- Interventions
- Modified CariesCare International management
- Procedure
- Lead sponsor
- Universidad El Bosque, Bogotá
- Other
- Eligibility
- 3 Years to 8 Years
- Enrollment
- 409 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Two IM injections Lenti-HPV-07, One IM injection Lenti-HPV-07
- Drug
- Lead sponsor
- Theravectys S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Orlando, Florida • Tampa, Florida • Tulsa, Oklahoma
- Conditions
- ARDS, Human, Lung, Wet, Thyroid, Pulmonary Edema, Lung Inflammation
- Interventions
- Liothyronine Sodium (T3+0.9% sodium chloride) modified formulation specifically for airway instillation., Non-intervention
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Edina, Minnesota • Minneapolis, Minnesota
- Conditions
- Obesity, Morbid, Bariatric Surgery Candidate, Diet Habit, Behavior, Social, Physical Activity
- Interventions
- Attendance
- Behavioral
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- HIV Infections
- Interventions
- Infección de Amor (Infectious Love)
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 44 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Bone Loss, Alveolar
- Interventions
- Zimmer T3 Short Ex Hex With Discrete Crystalline Deposition, Zimmer T3 with Discrete Crystalline Deposition Ex Hex Parallel Walled implants
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Edentulous Jaw
- Interventions
- T3 dental implant system
- Device
- Lead sponsor
- ZimVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- Gainesville, Florida • Neptune City, New Jersey • Richmond, Virginia
- Conditions
- Cutaneous Squamous Cell Carcinoma of the Head and Neck
- Interventions
- Ultrasound
- Diagnostic Test
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • Baltimore, Maryland
- Conditions
- Caregivers
- Interventions
- webcasts, Assessments, Usual care
- Other · Behavioral
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Major Depression
- Interventions
- Triiodothyronine, Placebo, Sertraline
- Drug · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer
- Interventions
- Cisplatin, Postoperative radiotherapy
- Drug · Radiation
- Lead sponsor
- Lisette Nixon
- Government
- Eligibility
- 18 Years and older
- Enrollment
- 1,269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2028
- U.S. locations
- 3
- States / cities
- Redwood City, California • Orlando, Florida • Houston, Texas
- Conditions
- Rectal Cancer
- Interventions
- Chemo with concomitant Capecitabine and KD018
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Hypothyroidism, Brain Tumor
- Interventions
- Levothyroxine, Liothyronine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas